Nexavar Net Sales increase 107% over Second Quarter 2007
EMERYVILLE, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the three and six months ended June 30, 2008. Onyx reported net income of $4.5 million, or $0.08 per diluted share, for the second quarter of 2008 compared to a net loss of $10.8 million, or $0.22 per diluted share, in the same period in 2007. Excluding employee stock-based compensation expense, non-GAAP net income for the second quarter of 2008 was $8.7 million, or $0.15 per diluted share, compared to a non-GAAP net loss of $7.2 million, or $0.15 per diluted share, in the same period in 2007. A description of the non-GAAP calculations is provided below in the accompanying Reconciliation of GAAP to Non-GAAP Net Income.
Global Nexavar net sales as reported by Bayer HealthCare Pharmaceuticals, Inc., or Bayer, were $168.5 million for the quarter ended June 30, 2008, a 107% increase over the $81.3 million reported in the same period in 2007. Onyx with its collaborator, Bayer, is marketing and developing Nexavar(R) (sorafenib) tablets, an anticancer therapy currently approved for the treatment of liver cancer and advanced kidney cancer in the U.S., European Union, and other territories internationally.
"We are pleased with the strong revenues and continued momentum for
Nexavar globally with net sales reaching $168.5 million in the second
quarter, indicating expanding global demand for the brand. Based on a
series of rolling launches worldwide, we expect to see additional growth
opportunities for Nexavar, particularly for the treatment of liver cancer,"
said Tony Coles, M.D., president and chief executive officer of Onyx. "With
|SOURCE Onyx Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved